---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-103974"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:27:01.080628+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98

## Summary
- Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.
- KEYTRUDA sales $8.1B (+10%); WINREVAIR $360M (+141%); GARDASIL down 24% to $1.7B.
- Full-year 2025 sales guidance raised to $64.5-65.0B; non-GAAP EPS raised to $8.93-8.98.
- Completed acquisition of Verona Pharma (OHTUVAYRE) in October 2025.
- FDA approved KEYTRUDA QLEX subcutaneous injection for all solid tumor indications.

## SEC filing metadata
- accession: 0001104659-25-103974
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/0001104659-25-103974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-103974
- JSON: https://secwatch.observer/filing/0001104659-25-103974.json
- Plain text: https://secwatch.observer/filing/0001104659-25-103974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.